Cost-effectiveness of human papillomavirus vaccination in Germany

Table 4 Indirect costs

Parameter	Average absence from work (days)^a	Indirect costs (€, 2010 price level)^b
Treatment of CIN 1 and CIN 2	15.9	15–19 years	336.50
		20–24 years	835.26
		25–29 years	965.33
		30–34 years	977.31
		35–39 years	1009.89
		40–44 years	1063.18
		45–49 years	1060.82
		50–54 years	1010.30
		55–59 years	853.97
		60–64 years	410.89
Treatment of CIN 3 and CIS	21.3	15–19 years	450.79
		20–24 years	1118.93
		25–29 years	1293.18
		30–34 years	1309.23
		35–39 years	1352.87
		40–44 years	1424.25
		45–49 years	1421.10
		50–54 years	1353.42
		55–59 years	1144.00
		60–64 years	550.44
Treatment of cervical cancer (all FIGO stages)	44.4	15–19 years	939.67
		20–24 years	2332.42
		25–29 years	2695.65
		30–34 years	2729.11
		35–39 years	2820.06
		40–44 years	2968.87
		45–49 years	2962.30
		50–54 years	2821.22
		55–59 years	2384.68
		60–64 years	1147.39
Death due to cervical cancer (all FIGO stages)	63 (friction period)	15–19 years	1333.31
		20–24 years	3309.52
		25–29 years	3824.91
		30–34 years	3872.38
		35–39 years	4001.44
		40–44 years	4212.58
		45–49 years	4203.26
		50–54 years	4003.08
		55–59 years	3383.67
		60–64 years	1628.06
Treatment of genital warts in females	7.7	15–64 years	30.81^c
Treatment of genital warts in males	8.7	15–64 years	28.14^c

CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, FIGO International Federation of Gynecology and Obstetrics
^aAverage duration of absence from work in patients who missed work because of illness
^bWeighted by age-specific employment rates of women
^cNot weighted by age-specific employment rates as the fraction of genital warts patients who missed work was estimated directly on the basis of a German study [42]

ISSN: 1478-7547